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“The Relationship Between Tamoxifen and Depressive
Symptoms in Women with Breast Cancer”
by
Terry Marie Lynn
The purpose of this study was to determine whether women with breast cancer
and the presence of the drug tamoxifen, are more severely depressed than women with
breast cancer and the absence of tamoxifen. Average Beck Depression Inventory (BDI)
scores did not differ between the two sub-groups; however, two significant group
differences were found. First, 10 women in the tamoxifen group had scores of zero
(versus 4 in the absence of prescribed tamoxifen group). Research has shown that scores
of zero do not always reflect an absence of depression. Second, the most severely
depressed women (BDI scores in the 25 to 31 range) were also members of the tamoxifen
group. These results suggest that for the women taking tamoxifen at the time of the
study, a history of depression was associated with more severe depressive symptoms.
Finally, among women without tamoxifen, several had discontinued tamoxifen therapy
because of depressive side effects.
Introduction
Breast cancer is the most common cancer among women, accounting for one out
of every three cancer diagnoses. In 1997, for example, approximately 181,600 new cases
of invasive breast cancer are expected to be diagnosed, and 43,900 women are expected
to die from this disease (American Cancer Society, 1997).
The incidence of breast cancer mortality increases with age, and about three
quarters of all women with new diagnoses of breast cancer are over the
age of 50. Breast cancer is relatively uncommon in younger women, with an incidence
rate of one case per 100,000 for women ages 20-24. However, the rate climbs to 25.2
cases for women ages 30-34, 125.4 for women 40-44, and 232.7 for women 50-54
(Kosary, Ries, & Miller, 1995). Although heart disease is the leading cause of death in
women in the United States, breast cancer is the leading cause of death in women between
the ages of 40 and 55 (Henderson, 1995).
Treatment decisions are made by the patient and the physician after considering
the optimal treatment for the stage and type of cancer, the patient’s age and preferences.
and risks and benefits ascribed to each treatment protocol. Most patients are successfully
treated for breast cancer with local procedures, such as surgery in the form of a modified
mastectomy or lumpectomy, followed by radiation therapy, chemotherapy, peripheral stem
cell transplantation, and hormonal therapy (McClay, Albright, & Jones, 1994; Murphy,
Lawrence, & Lenhard, 1995; Williams, O’Sullivan, Snodgrass, & Love, 1995).
Hormonal therapy in the form of tamoxifen (trade name: Nolvadex) is
the most widely used adjuvant treatment worldwide for early stage breast cancer
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(Ganz, Day, Ware, Reedmond, & Fisher, 1995; Hayes et al., 1995). Multiple studies have
demonstrated that tamoxifen can significantly reduce the possibility of breast cancer
recurrence and death (Ganz et al., 1995; Hayes et al., 1995). Tamoxifen is a nonsteroidal
antiestrogen that competitively blocks estrogen receptors in breast cancer cells. In
primary breast cancer, adjuvant tamoxifen therapy following surgery produces a 20
percent reduction in disease recurrence at ten years, as well as a 40 to 50 percent
reduction in new breast cancer in the opposite breast. Tamoxifen has also been shown to
produce clinical benefits in at least 33 percent of women with metastatic breast cancer,
independent of hormone receptor status, and in 50 percent of women with estrogen
receptor-positive breast tumors (Zeneca Pharmaceuticals, 1995).
A brief review of the evolution of tamoxifen in its present and sometimes
controversial status began in 1954. Originally, tamoxifen was limited to the treatment of
postmenopausal women with breast cancer. When compared with other antiestrogens,
tamoxifen was reported to be equally effective and better tolerated. The adverse effects
related to tamoxifen were reported to be less severe than those seen with other hormonal
treatments. Today, hopes for improved survival and well-being have increased because of
advances in early detection, changes in surgical techniques, and progress in systemic
therapy. Because of its favorable adverse-effect tamoxifen has become the endocrine
therapy of choice (Higa, 1994).
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Tamoxifen causes few known debilitating side effects (Costa & Jordan, 1991;
Love, Leventhal, Easteling, & Nerenz, 1989); however, the documented side-effect
reports point to a decrease in quality of life (Love et al., 1989). For example, the
most frequently reported side effects are menopausal symptoms and nausea
(Fisher, Constantino, & Redmond, 1989). The next most frequent side effects include
fatigue/tiredness, gynecological symptoms (e.g., vaginal discharge, irritation, and
bleeding), depression and anxiety. There may also be a rare incidence of visual
disturbances (Doig, 1988; Kaiser-Kupfer & Lippman, 1978; Nayfield, Karp, Ford, Dorr, &
Kramer, 1991; Nolvadex Adjuvant Trial Organization, 1985). Despite the clinical reports
that depression can accompany the use of tamoxifen, the relationship has not been well
studied. According to Cathcart et al. (1993):
Depression is commonly diagnosed in patients with cancer including breast cancer
and therefore it is relatively easy to overlook as a potential side effect of one of the
common drugs used to treat breast cancer. Depression has long been recognized
as a possible side effect of tamoxifen, but only in recent years has it been given
noteworthy status, (p. 280)
Theoretical Framework for the Study
Systems theory is a large domain that has had a major effect on the theory
and practice for those who work with cancer patients. It involves those concepts
that emphasize reciprocal relationships between the elements that constitute a
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whole. These concepts also emphasize the relationships among individuals,
groups, organizations, or communities and mutually influencing factors in the
environment ( Barker, 1996; Newby, 1996).
A system is composed of subsystems, each with its own function. The
systems-oriented biopsychosocial model is an example of a set of three subsystems. The
biopsychosocial approach to therapy builds an understanding of: biological perspectives,
psychological development, and the social components (e.g., influence of significant
others, significant environments and systems), as essential characteristics in the
development and maintenance of healthy and fulfilling human living. The knowledge base
of practice is drawn from the biological, psychological, and social components of human
growth and development and their interaction. To this knowledge base is joined an
understanding of the interrelatedness of the spectrum of systems in which persons
function. These functions include their strengths and weaknesses, their potentials and
limitations, which combine to form a more complete system. On this knowledge base are
developed skills in engaging responsibly and effectively in therapeutic and helping
relationships with individuals, families, groups, and significant environments to bring
about planned change in human functioning. Specifically, it seeks to understand persons
in the context of their current reality and to use this understanding in a therapeutic way in
the treatment of biological, psychological, personal, interpersonal, and social problems and
their relationships (Turner, 1986). The theory’s emphasis on interdependence and
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interaction among systems components and its interest in what makes social systems
adaptive or maladaptive are two important reasons for its usefulness in medical social
work practice.
Medicine has appropriated the biopsychosocial model as a conceptualization of the
systemic interrelationships among the biological, the psychological, and the social in health
and illness (Engel, 1980). Utilizing the framework of biopsychosocial assessment model,
this study begins to meet the needs for empirical inquiry into the interrelatedness of these
subsystems, in the identification of the relationship between tamoxifen and symptoms of
depression in women with breast cancer (see Figure 1).
Biological Perspective
The most widely used antiestrogen agent to prevent or delay the growth of breast
tumors is tamoxifen, an antiestrogen with complex pharmacology encompassing variable
species-, tissue-, cell-, gene-, age- and duration of administration-specific effects, from
oestrogen-like agonist actions to complete blockade of oestrogen action (Bruzzi, 1998).
In vitro, tamoxifen inhibits the uptake and metabolism of estrone sulfate to estradiol
(Lonning, Johannessen, & Lien, 1995). In addition to the direct antiestrogenic effect, use
of tamoxifen in combination with chemotherapy may delay the development of resistance
to selected agents (McClay, Albright, & Jones, 1994).
Two studies indicate that depression may be a side effect of tamoxifen treatment.
Cathcart et al. (1993), assessed 257 patients with node-negative breast cancer who were
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on tamoxifen therapy and found that 15 percent of those on tamoxifen had major
depression versus only 3 percent of the control group. Shariff, Gumming, Lees, Handman,
and Gumming (1995), noted an increase in depression over an 8-month period in women
with early stage (I or II) breast cancer receiving adjuvant tamoxifen, despite no significant
increase in state anxiety or anger levels. The source of this depression is unclear because
other neuroendocrine alterations have been reported following tamoxifen therapy.
Mamby, Love, and Lee (1995), noted that tamoxifen therapy in postmenopausal women
may result in altered thyroid function.
Psychological Perspective
Kaplan and Sadock (1998), reported that “When people learn that they have
cancer, their psychological reactions include fear of death, disfigurement, and disability;
fear of abandonment and loss of independence; fear of disruption in relationships, and role
functioning; and denial, anxiety, anger, and guilt” (p. 813). It has also been noted that
patient responses to a diagnosis of cancer are modulated by medical, psychological, and
interpersonal factors. The medical factors include the location of the cancer in the breast,
the symptoms, and the prognosis. The psychological factors include the patient’s
personality traits, coping ability, ego strength, and developmental stage of life and the
consequences of the cancer at that stage (Kaplan & Sadock, 1995).
In a study by Packard, Haberman, & Woods (1991), the demands of illness
reported by women with breast cancer included three types: the direct effects of the
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disease, the personal disruption that occurs as a consequence of the illness, and the
environmental transactions necessitated by the illness. The direct effects of the illness
included physiological experiences such as fatigue, pain, and nausea. Personal disruptions
included challenges to the woman’s sense of integrity, continuity, and normalcy.
Disruptions in integrity included changes in self-perception, such as altered body image,
whereas disruptions in the sense of continuity in daily life included preoccupation with
both the personal meaning of the illness and attributions about the illness. Disruptions in
normalcy included the necessity of monitoring changes in bodily sensations and functions.
Social Perspective
It has been noted that sources of help outside the immediate family tend to
consider the crisis over once the ill person is home and resuming normal activities.
Friends may offer less help due to the fact that they may not be aware of the continuing
treatment that may be necessary after the initial diagnosis. This in turn, contributes to the
women’s perception of reduced support (Dhooper, 1984; Primomo, Yates, & Woods,
1990).
An important determinant of cancer patients’ ability to live with their illness is their
social environment. Environmental transactions resulting from the illness include
difficulties in relationships with members of social networks (e.g., husband, family,
religious and work groups) or with health care providers. Therefore, women often
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seek other sources of social support such as breast cancer support groups, which provide
positive affirmation, and valuable assistance, to reduce the demands women associate with
their illness. These social supports can influence how a family experiences the impact of
this illness (Dunkel-Schetter, 1984; Lindsey, Norbeck, Carried, & Perry, 1981; Wortman,
1984).
The demands of a chronic illness often precipitate changes in psychosocial
functioning and marital adjustment. The psychosocial results of the illness extend in a
ripple effect from patient to the entire family system. Each family member’s reaction to
illness and coping responses reverberates throughout the whole family and back again.
Stress associated with a disease process affects adaptation for those responding to cancer
(Gotay, 1984; Moos & Tsu, 1977; Strauss & Glaser, 1975).
An important element in systems theory is the concept of homeostasis. Essentially,
systems are said to operate in a range of stability. When something threatens this stability,
feedback signals the systems to activate error-correcting responses to reestablish
homeostasis (Wachtel & Wachtel, 1986). Changes affecting one part of the system (e g.,
physical and emotional well-being of the woman who may be both wife and mother
dealing with breast cancer) may precipitate changes in another part of the system (eg.,
physical and emotional well-being of the husband and children), thus altering the nature of
the relationships and creating disequilibrium. How the family seeks to reestablish
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homeostasis will have an effect on the woman with breast cancer (Gotay, 1984; Moos &
Tsu, 1977; Strauss & Glaser, 1975).
Support groups are established to provide relief from depression, reassurance.
practical information, guidance, and enhanced coping skills that enable members to regain
stability as they share their experiences. It has also been reported that there appears to be
a near doubling of survival rates in women who were treated with the specific group
psychosocial intervention of supportive-expressive group therapy (Fawzy & Fawzy, 1994;
Spiegel, Bloom, Kraemer, & Gottheil, 1989; Spiegel & Glafkides, 1983). This
intervention emphasizes intrapersonal aspects (e.g., emotional expressiveness, relaxation
training, expression of grief and depression, and confrontation with the existential
concerns of living life fully in the face of death), interpersonal aspects (e.g., group
cohesion, and enhancing communication skills with family and health care workers), and
community support from numerous area organizations.
As previously stated, Cathcart et al. (1993), and Shariff et al. (1995) noted an
increase in depression that may be a side effect of tamoxifen treatment. The source of this
depression was unclear, and would seem to indicate continued research. The primary
purpose of the present study is to evaluate the relationship between tamoxifen and
depressive symptoms in women with breast cancer.
Three research questions were developed: (1) Are women with breast cancer
where tamoxifen is present more depressed than women where tamoxifen is absent,
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(2) Among patients where tamoxifen is present, are depressive symptoms more severe in
those who have a history of depression prior to having breast cancer, and (3) Among




Women who have had a diagnosis of breast cancer were eligible to participate. A
convenience sample of women was drawn from breast cancer support groups sponsored
by the American Cancer Society and facilitated by licensed psychologists, social workers,
and physicians. A total of 240 packets were sent to various support groups in California,
Arizona, and Wisconsin. A total of 153 women participated in the study, with 13
instruments being unusable due to incompletion of questions (response rate = 64%; valid
response rate = 58.3%). The average age of the women was 60 years (SD = 12); age
range = 37 to 90.
Instruments and Procedure
Participants were asked to complete a short questionnaire about themselves and
their breast cancer treatment. Questions asked included, age and when first diagnosed
with breast cancer, whether they had a lumpectomy or mastectomy and reconstruction.
Questions about treatment included whether they had chemotherapy, radiation therapy, or
stem cell/bone marrow transplantation. Other questions asked about
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estrogen and tamoxifen (whether they were taking estrogen and tamoxifen, andwhether
they discontinued either). For those who had discontinued tamoxifen, questions were
asked about reasons and side effects. The final set of questions pertained to a history of
depression.
Participants also were asked to complete two standard psychological scales: the
Beck Depression Inventory (BDI) (Beck & Steer, 1987) and the state portion of the State-
Trait Anxiety Inventory (STAI) (Spielberger, Gorsuch, Lushene, Vagg, & Jacobs, 1983).
This author’s primary interest was in depressive symptoms, it is common practice when
assessing mood to also assess anxiety symptoms. These two instruments are among the
most widely used self-report depression and anxiety scales, and each has demonstrated
adequate reliability and validity (Beck & Steer, 1987; Spielberger, Gorsuch, Lushene,
Vagg, & Jacobs, 1983).
Questionnaires were distributed in batches to support group facilitators who
disbursed and collected them at support group meetings.
Statistical Analyses
To evaluate group differences in mean depression and anxiety scores, t-tests for




A total of 105 (75%) of the women reported having a mastectomy, 51 (36.4%)
had a lumpectomy, and 32 (22.9%) had reconstruction. There were 69 (49.3%) women
who had chemotherapy, 54 (38.6%) who had radiation, 6 (4.3%) stem cell, and 81
(57.9%) who at one time or another took tamoxifen. Of those who took tamoxifen, 54
(66.7%) were still on the drug while 27 (33.3%) of the women had discontinued therapy.
Of those who had discontinued tamoxifen, 19 (70.4%) reported side effects such as hot
flashes, interrupted sleep, rashes, dizziness, severe headaches, feeling ill, blood clots, and
problems with their eyes and liver. Eight women (29.7%) reported severe depression (see
Table 1).
The subjects were asked if they had been taking estrogen prior to the diagnosis of
breast cancer. Sixty (42.9%) reported they had been taking estrogen with 56 (40%)
discontinuing to take the medication once diagnosed with breast cancer.
Of the 140 participants, 25 (17.9%) reported having a history of depression prior
to their diagnosis, and 14 (10%) stated they had been in treatment prior to the breast
cancer. There were 13 (9.3%) taking medication for depression, and 8 (5.7%) reported
being in therapy.
The women’s (n = 140) BDI scores ranged from 0 to 31, and the mean score was
7.2 (SD = 6.2). The mean BDI score for women where tamoxifen was present (n = 68)
was 7.5 (SD = 7.3), and the mean score for women where tamoxifen was absent (n = 50)
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was 6.8 (SD = 4.4). The mean difference was not statistically significant. (Depression
and anxiety scores by tamoxifen group are displayed in Table 2).
A breakdown of the BDI scores by the presence or absence of tamoxifen is shown
in Table 3. Although the mean difference was not statistically significant, the groups
differed in two important ways. First, 10 women in the group where tamoxifen was
present had scores of zero (versus 4 in the not taking tamoxifen group). This is
noteworthy because BDI scores of zero do not always reflect absence of depression (Field
et al., 1991). Second, the most severely depressed women (BDI scores in the 25 to 31
range) all were in the group where tamoxifen was present.
Anxiety scores (n = 140) ranged from 20 to 73 (M = 35.8, SD = 12.4). The mean
scores for women where tamoxifen was present (n = 71) versus where tamoxifen was
absent (n = 52) were 37.7 (SD = 13.5) and 33.2 (SD = 10.1), respectively. The difference
was statistically significant, t = 2.05, df = 121, p = .04). The crosstabulation of anxiety
scores by tamoxifen status is shown in Table 4; as expected, severe anxiety is more
common among women where tamoxifen was present.
A total of 48 women in the group where tamoxifen was present answered the
question about having a history of depression; six had such a history, and 42 did not. The
mean BDI score for women with a history of depression was 8.8 (SD = 6.7) whereas the
mean for women with no such history was 6.4 (SD = 4.1). There were too few women in
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the history of depression group (n = 6), however, to conduct a valid test of statistical
significance.
Discussion
The main purpose of the present study was to evaluate depressive symptoms in
women with breast cancer where tamoxifen was present, and to determine whether those
women are more depressed than those where tamoxifen was absent; to determine whether
depressive symptoms are more severe for women where tamoxifen was present who have
experienced depression prior to diagnosis of their breast cancer; and among women where
tamoxifen was absent, how many discontinued therapy because of feelings of depression.
Women in several breast cancer support groups were eligible participants of this
study. Two standard depression and anxiety instruments were used, the Beck Depression
Inventory and the state portion of the State-Trait Anxiety Inventory. Although the mean
BDI scores for women where tamoxifen was present and women where tamoxifen was
absent were not statistically significant, the groups differed in two important ways. First,
10 women in the tamoxifen group had scores of zero, versus 4 in the group where
tamoxifen was absent. This is noteworthy because BDI scores of zero do not always
reflect absence of depression. Second, the most severely depressed women (BDI scores in
the 25 to 31 range) all were in group where tamoxifen was present.
Mean anxiety scores were comparable among the group where tamoxifen was
present and the group where tamoxifen was absent. Similar to the depressive symptoms
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analysis, the study also indicated that the women where tamoxifen was present were more
anxious than the women where tamoxifen was absent. The mean scores for women where
tamoxifen was present versus the group where tamoxifen was absent were statistically
different. The crosstabulation of anxiety scores by tamoxifen status also showed that
severe anxiety is more common among women where tamoxifen was present.
Of the 140 participants, 17% reported having a history of depression prior to their
diagnosis, 10% stated they had been in treatment prior to the breast cancer, 9% were
taking medication for the depression, and 5% reported being in therapy. Of thosewomen
who discontinued tamoxifen, 8 reported severe depression. Side effects such as hot
flashes, interrupted sleep, rashes, dizziness, severe headaches, feeling ill, blood clots, and
problems with their eyes and liver were described by those who had discontinued
tamoxifen.
The Finder et al. (1993) study shows that almost 50% of all cancer patients suffer
from clinically relevant depressions and severe anxiety. Of women with advanced breast
cancer, 25% showed anxiety and depression. The scores obtained from my research
indicate that 10 women in the group where tamoxifen was present had scores of zero on
the BDI, and the most severely depressed women were in the group where tamoxifen was
present. There is a possibility that the women who scored zero on the BDI may not be
aware that they are experiencing depression, due to the fact BDI scores of zero do not
always reflect absence of depression (Field et al, 1991).
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There are a couple of interpretations for a zero BDI score. In some cases it may
reflect a denial of depression. Another process such as avoidance or “faking good” may
result in a zero score. The women may also not report depression due to the fact that they
may see themselves as angry and irritable and not realize that these are also signs of
depression (Field et al., 1991). Their anger and irritability, as well as “faking good,” may
contribute to the high level of anxiety that has been reported in this study. The “faking
good” may be a result of women believing that their depression is caused by the
circumstance of having a diagnosis of breast cancer, when in fact, it may be caused by a
reaction to the tamoxifen. There is a general social attitude that once the surgery is
completed, the woman needs to put the experience behind her and get on with life.
For most women, a diagnosis of breast cancer marks the beginning of a life-long
struggle. The disease and treatments become biopsychosocial stressors whose effects
linger long after the individual is tumor-free. The effects are often widespread. Breast
cancer is associated with anxiety and depression, not only in those who are affected but in
their families and loved ones as well (Holland, 1989).
A review of the literature revealed a general agreement that there is a continuing
disparity of the terms anxiety and depression, each of which refers to different types,
levels, or combinations of the disorder. For this paper anxiety is defined as a feeling of
apprehension, worry, uneasiness, or dread, especially of the future. It is the normal
reaction to that which is threatening to the body, lifestyle, values or loved ones (Thomas,
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1985). Anxiety is best predicted by panic symptoms, thoughts of pain or physical
discomfort, worry and tension. Clients find it difficult to describe anxiety and may use
such words as tense, panicky, terrified, jittery, and nervous in trying to delineate the
sensation (Clark, Beck, & Beck, 1994; Kaplan & Sadock, 1995).
Approximately 20-50 percent of cancer patients have coexisting psychiatric
diagnoses, most often depression and anxiety (Bukberg, Penmen, & Holland, 1984;
Derogatis, Morrow, & Petting, 1983; Massie & Holland, 1990). The presence of
symptoms of depression, and anxiety in cancer patients falls well within the range of
normal human response to catastrophic life events, making it difficult to distinguish
between a normal reaction to a diagnosis of cancer and one that manifests psychiatric
illness. In addition, many of the symptoms of cancer and the effects of cancer therapy
mimic depression, such as hopelessness, low energy, or anorexia (Kathol, Mutgi, &
Williams, 1990; Kathol, Noyes, & Williams, 1990).
This study shows that for women who may have a propensity to be depressed are
more likely to be at risk for severe depression when taking inhibiting drugs. This risk
factor appears to be significant enough that the researchers involved in the National
Surgical Adjuvant Breast and Bowel Project Breast Cancer Prevention Trial conducted
extensive screening of all the participants. In this study the health related quality of life
was evaluated extensively. An assessment was taken to identify medical background,
family and social relations, and a psychological evaluation that would reveal any
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propensity for depression. Of particular concern was clinical depression, sexual
functioning, and menopausal symptoms. It was noted that additional instruments were
administered to eliminate those participants with active symptoms of depression (Ganz,
Day, Ware, Redmond, & Fisher, 1995).
The loss of interest in pleasurable activities such as food, sex, work, friends.
hobbies and entertainment are also characteristics of depression. Cassem (1990) has
attributed four additional symptom criteria to a serious, life-threatening illness: insomnia,
diminished ability to think or concentrate, recurrent thoughts of death, and possibly
markedly diminished interest or pleasure in almost all activities.
This clinical observation is further supported by the fairly rapid onset of depression
in the first two months of therapy for most patients, and the prompt reduction or cessation
of therapy should be considered. Cathcart et al. (1993) stated that: “Occasionally the
symptoms were subtle, with patients complaining of‘feeling bad’ or ‘fatigue’ since
starting tamoxifen, and only careful questioning elucidated classic symptoms of
depression” (p. 279) .
It is an accepted fact that women who receive the ultimate diagnosis of having
breast cancer exhibit depression and anxiety. The many presenting biological symptoms
tend to veil the secondary depression caused by the tamoxifen therapy. Although this
secondary effect has been recognized, until recently it has received only minimal attention,
as there are other side affects that are more obvious. These side effects include
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gynecological bleeding, discharge, and irritation, hot flashes, nausea, inability to
concentrate, sleep disturbance, headaches, and agoraphobia (Cassem, 1990; Cathcart et al,
1993; Me Daniel, Mussehnan, Porter, Reed, & NemerofF, 1995; McDaniel, Rhodes,
Velson, & Hanson, 1995).
Recognition of severe and persistent depression and anxiety is important. Apart
from the acute stress response, reactive depression is the most frequent psychological
problem encountered among patients with cancer (Hayes et al., 1995). The acute stress
response, which occurs at pivotal points during the course of illness, is normal. However,
severe or protracted depressive symptoms should be evaluated and treated. Thus,
diagnosis must rely heavily on psychological symptoms, including the presence of
dysphoric mood (sadness, anxiety) and feelings of hopelessness, helplessness, and
worthlessness. Cancer patients who are at highest risk for developing depression are
those with a history of prior depression or psychiatric illness. In an analysis of newly
diagnosed breast cancer patients assessed for levels of psychological distress, a high
correlation was found with prior history of depression. The treatment of depression can
result in improved compliance with therapy, a greater tolerance for the disease
and its outcome, and an improved quality of life (Sachs et al., 1995; Spiegel, Bloom,
Kraemer, & Gottheil, 1989).
Women who have been diagnosed with breast cancer may experience a variety of
different feelings. To some women, the breast may represent femininity, sexuality, love,
20
nurturance, and maternal feelings, it is therefore often an important part of her self-image.
Feelings of anxiety, anger, and depression are not uncommon. She may also view the loss
of her breast as an assault, while at the same time, she is also dealing with the fact that she
has cancer and the threat that the diagnosis has to life itself
Baird (1991) presented the belief that women undergoing a mastectomy may have
feelings of mutilation, a decrease in self-image, feelings of despair, helplessness, shock,
guilt, personal vulnerability, and problems in sexual and family relationships. She further
indicated that these feelings also have an impact on the spouse or significant other and the
family.
As the woman struggles with the biological, social, and psychological components
and their interactions, she may experience emotion-focused coping as a form of reality
distortion in which the person changes the meaning of a stressful situation. Such
maneuvers are used to maintain hope, deny facts and implications, refuse to acknowledge
the worst, or to act as if what happened did not matter (Lazarus & Folkman, 1984).
Any surgical procedure as severe as a mastectomy might be expected to have
depressive consequences. The female breast with its feeding and sexual functions has such
a symbolic meaning that its amputation has serious consequences for the woman’s self-
image, her feelings of femininity and her social functioning (Renneker & Cutler, 1952).
However, Van Heeringen, Van Moffaert, & de Cuypere (1989), found no differences in
the depressive reaction between mastectomy and lumpectomy(breast conservation)
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patients. Van Heeringen et al., (1989) stated that: “the diagnosis of malignancy is a more
powerful factor in causing depressive symptoms than the mutilation itself,” (p. 178)
The grief women feel after a mastectomy precipitates a two-fold response, the first
is reactive which concerns the loss of the breast, the second, preparatory occurs when
women realize the life threatening potential of the disease. The diagnosis then becomes
the most dynamic factor in causing depression. It is even more debilitating than the
mutilation itself. Therefore, the preparatory element, which is common to both groups of
women, is the decisive factor in the development of depression.
Psychotherapy concentrates on the reactive response to depression by affording an
opportunity for women to discuss the future. In these small groups, empathic listening
may be the most important means for women to communicate their fear for this
progressive illness and subsequent health (Van Herringen et al. (1989).
There must be an opportunity for the women to communicate their fear for
progressive illness and possible death, and a time to acknowledge their grief reaction.
Taber’s Cyclopedic Medical Dictionary (Thomas, 1985) defines grief reaction as:
The emotional reaction that follows the loss of a love-object. Somatic symptoms
include easy fatigability, hollow or empty feelings in the chest and abdomen,
sighing hyperventilation, anorexia, insomnia, and the feeling of having a lump in
the throat. Psychological symptoms begin with an initial stage of shock and
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disbelief accompanied by an inner awareness of mental discomfort, sorrow, and
regret, (p. 708)
When women are not allowed to grieve properly, unresolved reactions and feelings
may lead to a higher level of discomfort, and these unresolved issues may continue to
prevent them from living life to the fullest. It is therefore important to discover the
secondary losses of breast cancer. For the young woman secondary losses may include
the loss of invincibility, femininity, and control over their lives and relationships. For older
women, the secondary loss is the sense of being cheated out of the “golden” years of
retirement (LaTour, 1993). She goes on to discuss that in the past women spoke in
hushed tones, letting her know that they had had ‘the operation’ too. They were expected
to have the stoic attitude of T’m going to beat this thing’, and get on with life (p. 250).
According to Michael Fitzpatrick, M.D., chief of Consultation-Liaison Psychiatry and
associate professor at the University of Texas Southwestern Medical School (in LaTour,
1993):
A woman can often be her own worst enemy in the resolution process as she tries
to protect herself and those around her. Women often need to deny that having
cancer has affected them. They want to make sure that their role-functioning is
not diminished in any way. They want to reassure everybody that they are the
same person. They want to protect their husbands or mates, children, and friends
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from fear associated with change and uncertainty by demonstrating that nothing is
different, at least externally. That’s an unhealthy process.
To deny loss has occurred only postpones the time when grief will reemerge in one
form or another. When delayed, it may later be experienced as physical exhaustion
or perhaps as subtle changes in behavior or personality—for example, shutting
people out, avoiding intimacy, indecisiveness, or general irritability. Sometimes
complicated grief emerges as clinical depression. There are times when grief
associated with earlier loss is experienced years later, (p. 253)
Additional secondary losses can be physical or symbolic. Depending on the type of
treatment, there can be the loss of a familiar home environment because of the stay in a
hospital room, or the loss of independence because of the illness and having to rely upon
others for care.
Breast cancer can have a devastating and often numbing effect. The women may
experience a loss of autonomy, predictability, pleasure, identity, hope, self-esteem, and
loss of control. Loss may result in a grief reaction, and may need to be mourned. The
meaning and extent of each loss varies for each person, depending upon the investment
that was made, thus the amount of grieving required varies from woman to woman.
Limitations of the Study
It is important to recognize the limits of this research study. This study used a
self-report instrument with a convenience sample drawn from individuals currently
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participating in breast cancer support groups. Because a convenience sample was used, it
may not be representative of all women in the breast cancer, particularly those who are not
involved with a support group. Moreover, the women in this convenience sample were
older (average = 60). Although the sample size was large enough to determine group
differences, some of the subgroup analyses for depression were not possible due to the
limited number of women in that targeted group (eg., there were too few women with a
history of depression to assess for statistical significance).
Other possible intervening variables not examined in this study included ethnicity,
socioeconomic status, length of time on medication, and length of time post surgery. In
future studies with larger samples, it possibly would be more illuminating if these variables
were measured and used in a more sophisticated multivariate analysis.
Finally, studies of this sort are thought to be stronger if both self-and-observer-
scales are used. Such reports from clinicians and family members are valuable in
determining the effect of life stressors such as divorce, recurrence of the cancer, the
families’ inability to come to terms with the disease, the lack of time allowed for the
women to grieve the loss of a body part, and the loss of life style.
Implications for Social Work Practice and Future Research
The role of the support group is extremely important in the life of a breast cancer
survivor. Van Heeringen, Van Moffaert, & de Cuypere (1989), states that “psychotherapy
aimed at the reactive element of the depression contains an optimistic support with
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cheering up, talking about the future, giving prosthetic advice...and dealing with the
diagnosis of cancer” (p. 178). This would appear to be the philosophy of the majority of
the support groups as espoused in the literature (Baird, 1991; LaTour, 1993; Love, 1990).
However, as social workers facilitating these support groups, it is our responsibility to
also acknowledge the grieving process that women need to experience, and to encourage
the women to recognize their needs and allow them to be expressed.
Furthermore, the causes of depression need to include the possible effects of
tamoxifen on some of the women. For those who are experiencing severe depression, it is
imperative that the social worker provide a list of resources that will enable the woman to
seek out the support needed such as clinical inpatient or outpatient treatment for
depression. It is also the social worker’s responsibility to discuss with treating physicians
the role that depression plays in patient care.
This research study has raised many questions about the relationship between
tamoxifen and depressive symptoms in women with breast cancer. There are three issues
that need to be addressed in future research: the severe depression experienced by some
women where tamoxifen was present, the anxiety reported by a substantial number of
women, and the reasons why these women might not have recognized their underlying
depression. Is this severe depression that is experienced by some women where tamoxifen
was present caused by a biological reaction, past or present psychological factors, or
sociological life-stressors? Although anxiety was reported by a large number of women in
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this study, there are many unanswered questions about its origin. Is it simply a response
to the primary disease, the side effects of the tamoxifen, unresolved grief, or the fear of the
ramification of the disease? To establish the reason why these women did not recognize
the underlying depression, it will be necessary to study the structure and attitudes of
support groups. Could they be over emphasizing the positive and not allowing time for
grief work? Research needs to be conducted to evaluate the treatment team’s belief that
the depression is due to menopausal symptoms. Furthermore, are the women suppressing
their feelings of depression because of social expectations and therefore do not recognize
the symptoms? These are but a few of the questions raised by this study.
Conclusion
The initial diagnosis of breast cancer begins a struggle of the biopsychosocial
subsystem that encompasses the life of many women. They are faced with the seemingly
insurmountable task of making medical choices, hormonal therapy choices, and the
decision of becoming a part of a support group. All of these decisions impinge on their
feelings of well being. Their whole lives must now change, as their focus is now on the
fact that they have breast cancer.
The primary purpose of this study was to evaluate the depressive symptoms of
women who were where tamoxifen was present as an adjuvant therapy. The Beck
Depression Inventory and the state portion of the State-Trait Anxiety Inventory were
administered. The results indicated that the women where tamoxifen was present scored
27
highest in depression on the Beck Depression Inventory. The scores obtained from this
research indicate that women who scored zero on the BDI may not be aware that they are
experiencing depression, due to the fact BDI scores of zero do not always reflect absence
of depression. Furthermore, the results indicated that the absence of anxiety was equal
between those where tamoxifen was present versus those where tamoxifen was absent.
Similar to the depressive symptoms identified on the BDI, the study also indicated that the
women where tamoxifen was present were more anxious than the women where tamoxifen
was absent.
With the advent of the disclosure that tamoxifen may prevent breast cancer in
women who are at high risk (National Surgical Adjuvant Breast and Bowel Project Breast
Cancer Prevention Trial), it is particularly important to continue to study the drug’s
adverse side effects.
The relationship between women with breast cancer 
and the biopsychosocial system.
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Table 1
Answers to the Question. “Why Did You Quit Taking Tamoxifen?”
i) Three months of hot flashes- raging, very hormonal
2) Could not tolerate- extreme hot flashes/rash
3) Only took for 7 years
4) Side effects-eyes, liver, extreme hot flashes
5) Developed a blood clot
6) After two weeks of taking tamoxifen I became very dizzy. The kind of dizziness
that comes on real fast, I stopped taking it.
7) Hot flashes, slight depression
8) Hot flashes and interrupted sleep
9) It’s been over 5 years
10) Doctor prescribed new medicine Fareston
ii) Doctor changed to Fareston
12) Super hot flashes





16) Severe headache as awakening-feeling ill
17) Because it made me very depressed and I was in cold sweat
18) Hair loss, hot flashes, severe depression
19) Menopausal symptoms, depression, and panic
20) Five years and quit
21) Took it for 5 years
22) Canada is a 3 year term
23) Took it for 5 years
24) I was on it for a year in 1982-at that time they only kept you on it for a year
25) Took for approximately 7 years and had hot, hot flashes
26) Took 2 years- had weight gain, leg cramps, and depression
27) Took 6 months- had menopause reactions
28) I was depressed and got a rash
29) Took for 7 years and had a recurrence
30) I was more depressed while taking tamoxifen
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Beck Depression Inventory Scores bv Presence and Absence of Tamoxifen
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State-Trait Anxiety Inventory (State Portion) bv Presence of Tamoxifen and Absence of
Tamoxifen
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Loma Linda University
“The Relationship Between Tamoxifen and Depressive Symptoms 
in Women With Breast Cancer”
Dear Facilitator:
Thank you for helping me with my research. Please tell the participants to not fill in their 
name and other demographic information on the second and third questionnaires. I only 
need to know the background information, and have all questions answered. Please 
include women who have never been on Tamoxifen.
The purpose of this study is to research three questions: (1) Are women with breast cancer 
who are taking tamoxifen more depressed than women who are not taking tamoxifen, (2) 
Among patients taking tamoxifen, are depressive symptoms more severe in those who 
have a history of depression prior to having breast cancer, and (3) Among women who are 
not taking tamoxifen, how many discontinued this therapy because of depression?
I would like to thank each participant for taking the time to answer these instruments. I 
am a breast cancer survivor. I had bilateral surgery six years ago, and have had 
reconstruction. I also facilitate a Breast Cancer Support Group.
If you have any questions please feel free to call me at home at 909-760-6593 or work at 
909-824-4315.
Thank you for your time and cooperation.
Sincerely,
Terry M. Lynn, MSW Candidate 





Your age is years?1.
When were you first diagnosed with breast cancer?2.
Yes No
Did you have a mastectomy?
Did you have a lumpectomy?4.
Did you have reconstruction?5.
6. Did you have chemotherapy?
Did you have radiation therapy?7.
8. Did you have stem cell/bone 
marrow transplantation?
a. Were you taking estrogen?9.
b. Did you go off the estrogen?
10. a. Did you take tamoxifen?
b. Are you still taking tamoxifen?
c. If no, please explain why not. Please 
be specific if side effects were involved.
Yes No
a. Have you had a history of depression 
prior to a diagnoses of breast cancer?
11.
b. Are you presently being treated for depression?
c. If yes, are you on medication for depression?
d. If yes, are you in therapy?
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